Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04211337 · ClinicalTrials.gov registry record · Phase 3

A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer

A Phase 3 study of Medullary Thyroid Cancer, sponsored by Loxo Oncology.

Active
Registry status
Phase 3
Development phase
291
Enrollment target
20
Study locations

NCT04211337 is a Phase 3 study of Medullary Thyroid Cancer that is active but no longer recruiting, run by Loxo Oncology. The registered enrollment target is 291 participants, roughly in line with the 296-participant average among 4 other Medullary Thyroid Cancer trials with a reported enrollment target. The trial reports 20 study locations across 14 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04211337, a Phase 3 study of Medullary Thyroid Cancer, is active but no longer recruiting, sponsored by Loxo Oncology.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
291 participants
Enrollment target
20
Study locations

Study Summary

The reason for this study is to see if the study drug selpercatinib is safe and more effective compared to a standard treatment in participants with rearranged during transfection (RET)-mutant medullary thyroid cancer (MTC) that cannot be removed by surgery or has spread to other parts of the body. Participants who are assigned to the standard treatment and discontinue due to progressive disease have the option to potentially crossover to selpercatinib.

Conditions Studied

Medullary Thyroid Cancer

Interventions

  • DRUG Cabozantinib
  • DRUG Selpercatinib
  • DRUG Vandetanib

Study Locations (20)

California

  • City of Hope National Medical Center - Duarte
  • UCLA Hematology/Oncology - Westwood (Building 100) - Los Angeles
  • University of California Davis (UC Davis) Comprehensive Cancer Center - Sacramento
  • Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center - Torrance

Ohio

  • University of Cincinnati Medical Center - Cincinnati
  • The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer Center - Columbus

Pennsylvania

  • University of Pennsylvania Hospital - Philadelphia
  • Thomas Jefferson University - Philadelphia

Victoria

  • The Alfred Hospital - Melbourne
  • Peter MacCallum Cancer Centre - Melbourne

Alabama

  • University of Alabama at Birmingham - Birmingham

Georgia

  • Emory University - Atlanta

Illinois

  • University of Chicago Medical Center - Chicago

Massachusetts

  • Massachusetts General Hospital - Boston

Trial Details

FieldValue
Enrollment Target 291 participants
Start Date 2020-02-11
Est. Completion 2027-11
Phase Phase 3

Sponsor

Loxo Oncology

14 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04211337

The ClinicalTrials.gov registry entry for NCT04211337 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 291 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 296-participant average among 4 other Medullary Thyroid Cancer trials with a reported enrollment target. The listed sponsor is Loxo Oncology, which has 14 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Medullary Thyroid Cancer appearing as the primary indexed condition, and to 3 interventions - of which Cabozantinib is the first listed.

NCT04211337 reports 20 study locations spanning 14 distinct geographic areas - top geographies include California, Ohio, Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT04211337 about?

NCT04211337 is a clinical study titled "A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer". The reason for this study is to see if the study drug selpercatinib is safe and more effective compared to a standard treatment in participants with rearranged during transfection (RET)-mutant medullary thyroid cancer (MTC) that cannot be removed by surgery or has spread to other parts of the body. ...

What is the current status of trial NCT04211337?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 291 participants. The study started on 2020-02-11. Estimated completion is 2027-11.

What conditions does trial NCT04211337 study?

This clinical trial studies the following conditions: Medullary Thyroid Cancer.

What interventions are being tested in trial NCT04211337?

The interventions under investigation include: Cabozantinib (DRUG), Selpercatinib (DRUG), Vandetanib (DRUG).

Who is sponsoring clinical trial NCT04211337?

This trial is sponsored by Loxo Oncology, which has 14 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04211337 being conducted?

This trial has 20 study locations across Alabama, California, Georgia, Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Medullary Thyroid Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Medullary Thyroid Cancer

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.